A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

NCT05336409 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

28

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic decision

Conditions

R/R CD19-Positive B-Cell Malignancies
Indolent Non-Hodgkin Lymphoma
Aggressive Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL: CNTY-101
BIOLOGICAL: IL-2
DRUG: Lymphodepleting Chemotherapy

Sponsor

Century Therapeutics, Inc.